A new US MM patient asked me if I knew of any trials of an new agent I had not heard about previously, MDX-1106. It turns back on the immune cells which MM turns off. Only phase I trials available at present.
I also see that another monoclonal antibody, ipilimumab's phase II trial continues to look promising, but has some odd side-effects...
No comments:
Post a Comment